A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

NCT06764186 · readout in 499 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Apices Soluciones S.L., SOLTI Breast Cancer Research Group.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

101actual

Sites

Country

Spain

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-01-07

actual

When the study began enrolling

Primary completion

2027-12-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-12-31

estimated

The whole study's end, after follow-up

First posted

2025-01-08

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-06

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Locally Advanced or Metastatic Breast Cancer

Interventions

Drug: Fulvestrant
Drug: Capivasertib

Primary outcome

what the primary-completion date above is the date OF

Time to next treatment (TTNT)

measured From start of date of first dose of capivasertib+fulvestrant treatment to date of the first subsequent anti-cancer therapy or death or up to within approximately 12 months after Last Subject Inclusion

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed